Cargando…
Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively ana...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487126/ https://www.ncbi.nlm.nih.gov/pubmed/36127663 http://dx.doi.org/10.1186/s12883-022-02898-6 |
_version_ | 1784792426965106688 |
---|---|
author | Lu, Huanhuan Li, Siyi Zhong, Xin Huang, Shuxuan Jiao, Xue He, Guoyong Jiang, Bingjian Liu, Yuping Gao, Zhili Wei, Jinhong Lin, Yushen Chen, Zhi Li, Yanhua |
author_facet | Lu, Huanhuan Li, Siyi Zhong, Xin Huang, Shuxuan Jiao, Xue He, Guoyong Jiang, Bingjian Liu, Yuping Gao, Zhili Wei, Jinhong Lin, Yushen Chen, Zhi Li, Yanhua |
author_sort | Lu, Huanhuan |
collection | PubMed |
description | In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. |
format | Online Article Text |
id | pubmed-9487126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94871262022-09-21 Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment Lu, Huanhuan Li, Siyi Zhong, Xin Huang, Shuxuan Jiao, Xue He, Guoyong Jiang, Bingjian Liu, Yuping Gao, Zhili Wei, Jinhong Lin, Yushen Chen, Zhi Li, Yanhua BMC Neurol Research In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. BioMed Central 2022-09-20 /pmc/articles/PMC9487126/ /pubmed/36127663 http://dx.doi.org/10.1186/s12883-022-02898-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lu, Huanhuan Li, Siyi Zhong, Xin Huang, Shuxuan Jiao, Xue He, Guoyong Jiang, Bingjian Liu, Yuping Gao, Zhili Wei, Jinhong Lin, Yushen Chen, Zhi Li, Yanhua Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment |
title | Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment |
title_full | Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment |
title_fullStr | Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment |
title_full_unstemmed | Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment |
title_short | Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment |
title_sort | immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487126/ https://www.ncbi.nlm.nih.gov/pubmed/36127663 http://dx.doi.org/10.1186/s12883-022-02898-6 |
work_keys_str_mv | AT luhuanhuan immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT lisiyi immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT zhongxin immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT huangshuxuan immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT jiaoxue immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT heguoyong immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT jiangbingjian immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT liuyuping immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT gaozhili immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT weijinhong immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT linyushen immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT chenzhi immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment AT liyanhua immediateoutcomeprognosticvalueofplasmafactorsinpatientswithacuteischemicstrokeafterintravenousthrombolytictreatment |